Clinical Trials Network, Ohio Valley Node

描述(由申请人提供)： 俄亥俄山谷节点(OVN)四年前加入了NIDA的临床试验网络(CTN)，成为CTN的第二批受赠者之一。从一开始，OVN就是一个高效、热情和充满活力的节点，在提供科学和行政领导、与其他节点和NIDA工作人员合作以及传播关于循证做法和CTN研究结果的信息方面表现出色。此外，OVN还在其辛辛那提大学附属区域研究和培训中心(RRTC)与其位于俄亥俄州、印第安纳州、肯塔基州和西弗吉尼亚州的六个原创(“核心”)社区治疗项目(CTP)之间建立了双向模式关系。 在这一延续申请中，OVN提议通过扩大OVN在网络中的中西部和阿巴拉契亚地区的存在，并通过在另外五个州增加九个“特定于协议”的CTP，增加密西西比河三角洲的组成部分，从而加强CTN的地理和文化多样性。这15个OVN CTP每年总共治疗超过52,000名患者，这将大大增加CTN研究的潜在参与者的数量和种类。每个核心OVN CTP都参与了至少一项CTN临床试验和两项调查研究，所有六项研究都将继续参与该节点的管理及其研究概念和方案的制定。尽管新的特定方案的CTP将发挥更有限的作用，但他们热情地期待着参与适当的临床试验，为CTN提供更多和更丰富的患者群体。 在OVN在CTN的头四年里，我们完全沉浸在它的所有活动中。我们提交了九个议定书概念，其中五个被选定作进一步发展；两个已转变为完整的议定书，其中一个目前正在招募参与者。我们积极参与全国委员会的工作，提供了五名委员会主席，并编写或促成了许多标准作业程序和“指导”文件。OVN的独特贡献包括在CTN范围内用于监测和报告员工培训要求和成果的系统，用于跟踪CTN临床试验进展的系统，以及用于标准化CTN节点预算组织的模板。我们对这些成就和其他成就感到的满足感，再加上我们感到迫切需要继续努力寻找有效的药物滥用治疗方法，使我们急于继续我们已经开始的工作。

DESCRIPTION (provided by applicant): The Ohio Valley Node (OVN) joined NIDA's Clinical Trials Network (CTN) four years ago, as one of the CTN's second wave of grantees. From the very beginning, the OVN has been a highly effective, enthusiastic, and energetic node that has excelled in providing scientific and administrative leadership, in collaborating with other nodes and with NIDA staff, and in disseminating information about evidence-based practice and the results of CTN studies. Moreover, the OVN has developed a model bi-directional relationship between its University of Cincinnati-affiliated Regional Research and Training Center (RRTC) and its six original ("core") community treatment programs (CTPs), which are located in Ohio, Indiana, Kentucky, and West Virginia. In this continuation application, the OVN proposes to enhance the geographical and cultural diversity of the CTN by expanding the OVN's Midwestern and Appalachian presence in the network and adding a Mississippi Delta component, via nine additional "protocol-specific" CTPs in five additional states. The fifteen OVN CTPs, which together treat more than 52,000 patients a year, will contribute significantly to the number and variety of potential participants for CTN studies. Each of the core OVN CTPs has participated in at least one CTN clinical trial and two survey studies and all six will continue to share in the administration of the node and in its development of research concepts and protocols. Although the new protocol-specific CTPs will play a more limited role, they are looking forward with enthusiasm to participating in appropriate clinical trials, providing an expanded and enriched patient population to the CTN. During the OVN's first four years in the CTN, we have immersed ourselves fully in all of its activities. We have submitted nine protocol concepts, of which five were chosen for further development; two have been converted into full protocols, including one which is currently enrolling participants. We have been active in the national committees of the CTN, providing five committee chairs and authoring or contributing to many SOPs and "guidance" documents. Unique contributions by the OVN include a system used CTN-wide for monitoring and reporting on staff training requirements and accomplishments, a system for tracking the progress of CTN clinical trials, and a template used to standardize the organization of CTN node budgets. The sense of satisfaction we feel in these and other accomplishments, together with the urgency we feel to continue working on the important search for effective treatments for substance abuse, make us eager to continue the work we have begun.